{"id":"tp-52376","type":"article-newspaper","title":"Vir Biotechnology's Hepatitis Delta Combination Meets Phase 3 Goal","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/52376","datePublished":"2026-11-09T15:07:28.000Z","dateModified":"2026-11-09T15:07:28.000Z","language":"en","abstract":"At week 48, 44% of treated patients met the trial’s combined primary endpoint. No patients assigned to delayed treatment had met it at week 12.","section":"Business","references":[{"title":"ECLIPSE 2 and ECLIPSE 3 results","url":"https://www.tokenpost.com/news/business/49907"}]}